These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
565 related articles for article (PubMed ID: 17346246)
1. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Andermann F; Duh MS; Gosselin A; Paradis PE Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246 [TBL] [Abstract][Full Text] [Related]
2. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997 [TBL] [Abstract][Full Text] [Related]
3. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660 [TBL] [Abstract][Full Text] [Related]
4. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778 [TBL] [Abstract][Full Text] [Related]
5. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Makus KG; McCormick J Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825 [TBL] [Abstract][Full Text] [Related]
6. Generic products of antiepileptic drugs (AEDs): is it an issue? Bialer M Epilepsia; 2007 Oct; 48(10):1825-32. PubMed ID: 17850324 [TBL] [Abstract][Full Text] [Related]
7. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. Duh MS; Cahill KE; Paradis PE; Cremieux PY; Greenberg PE Expert Opin Pharmacother; 2009 Oct; 10(14):2317-28. PubMed ID: 19663636 [TBL] [Abstract][Full Text] [Related]
8. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Berg MJ; Gross RA; Tomaszewski KJ; Zingaro WM; Haskins LS Neurology; 2008 Aug; 71(7):525-30. PubMed ID: 18695164 [TBL] [Abstract][Full Text] [Related]
9. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy? Holtkamp M; Theodore WH Epilepsia; 2018 Jul; 59(7):1273-1281. PubMed ID: 29894004 [TBL] [Abstract][Full Text] [Related]
10. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100 [TBL] [Abstract][Full Text] [Related]
11. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens. Contin M; Alberghini L; Candela C; Benini G; Riva R Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080 [TBL] [Abstract][Full Text] [Related]
12. Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs. Bautista RE; Gonzales W; Jain D Epilepsy Res; 2011 Jun; 95(1-2):158-67. PubMed ID: 21530177 [TBL] [Abstract][Full Text] [Related]
13. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. Paradis PE; Latrémouille-Viau D; Moore Y; Mishagina N; Lafeuille MH; Lefebvre P; Gaudig M; Duh MS Curr Med Res Opin; 2009 Jul; 25(7):1793-805. PubMed ID: 19505202 [TBL] [Abstract][Full Text] [Related]
14. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Berg MJ; Gross RA; Haskins LS; Zingaro WM; Tomaszewski KJ Epilepsy Behav; 2008 Nov; 13(4):693-9. PubMed ID: 18589000 [TBL] [Abstract][Full Text] [Related]
15. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Zeng K; Wang X; Xi Z; Yan Y Clin Neurol Neurosurg; 2010 May; 112(4):291-5. PubMed ID: 20071075 [TBL] [Abstract][Full Text] [Related]
16. Does substitution of brand name medications by generics differ between pharmacotherapeutic classes? A population-based cohort study in France. Molinier A; Palmaro A; Rousseau V; Sommet A; Bourrel R; Montastruc JL; Bagheri H Eur J Clin Pharmacol; 2017 Apr; 73(4):471-477. PubMed ID: 28035437 [TBL] [Abstract][Full Text] [Related]
17. Economic burden associated with the use of generic antiepileptic drugs in the United States. Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619 [TBL] [Abstract][Full Text] [Related]
18. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987 [TBL] [Abstract][Full Text] [Related]